Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.1 USD | -0.15% | -2.73% | -19.45% |
04:20pm | Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
02:35pm | Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- With an expected P/E ratio at 139.38 and 12.35 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.59 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.45% | 81.3B | B- | ||
+32.68% | 704B | C+ | ||
+27.95% | 577B | B | ||
-4.54% | 348B | C+ | ||
+18.17% | 327B | B- | ||
+4.65% | 288B | C+ | ||
+14.60% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-4.69% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.